Parallel Advisors LLC Has $9.63 Million Stock Position in Gilead Sciences, Inc. $GILD

Parallel Advisors LLC raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 78,474 shares of the biopharmaceutical company’s stock after buying an additional 4,004 shares during the quarter. Parallel Advisors LLC’s holdings in Gilead Sciences were worth $9,632,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Total Wealth Planning & Management Inc. purchased a new position in Gilead Sciences in the fourth quarter valued at about $577,000. Prestige Wealth Management Group LLC grew its stake in Gilead Sciences by 314.5% in the fourth quarter. Prestige Wealth Management Group LLC now owns 4,746 shares of the biopharmaceutical company’s stock valued at $583,000 after purchasing an additional 3,601 shares in the last quarter. SlateStone Wealth LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $220,000. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new position in Gilead Sciences in the fourth quarter valued at about $2,383,000. Finally, Harvest Fund Management Co. Ltd grew its stake in Gilead Sciences by 14.4% in the fourth quarter. Harvest Fund Management Co. Ltd now owns 106,526 shares of the biopharmaceutical company’s stock valued at $13,075,000 after purchasing an additional 13,385 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Lakefront completed the acquisition of Ouro Medicines, expanding the company’s inflammation pipeline and adding gamgertamig, a potential first-in-class T cell engager for autoimmune diseases. This can support the stock by broadening long-term growth opportunities. Article Title
• Positive Sentiment: Gilead reported positive Phase 3 IDEAL trial results for Livdelzi in primary biliary cholangitis, including improved ALP normalization, which strengthens the case for a larger liver disease franchise and potential regulatory momentum. Article Title
• Positive Sentiment: Additional coverage highlighted favorable Livdelzi data and the company’s expanding liver and oncology footprint, which may reinforce confidence in Gilead’s growth pipeline. Article Title
• Neutral Sentiment: Coverage also noted that Gilead is drawing investor attention and being compared with other healthcare names, but these articles are more commentary than a direct new catalyst. Article Title
• Negative Sentiment: CEO Daniel Patrick O’Day sold 15,000 shares under a pre-arranged trading plan. While routine, insider selling can still weigh on sentiment for some investors. Article Title

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the completion of the sale, the chief executive officer owned 617,567 shares in the company, valued at $81,185,357.82. This represents a 2.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $132.27, for a total value of $396,810.00. Following the sale, the chief financial officer owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. The trade was a 1.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock worth $9,047,570 in the last 90 days. 0.30% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

GILD has been the topic of a number of recent research reports. Bank of America set a $162.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, February 11th. Leerink Partners lowered their target price on Gilead Sciences from $148.00 to $146.00 in a research note on Friday, May 8th. Wolfe Research upped their price target on Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, February 12th. Daiwa Securities Group decreased their price target on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, May 19th. Finally, Morgan Stanley decreased their price target on Gilead Sciences from $175.00 to $168.00 in a research note on Friday, May 8th. Twenty-six research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $156.93.

Gilead Sciences Stock Performance

GILD opened at $129.18 on Friday. The company has a market cap of $160.39 billion, a PE ratio of 17.60 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.77 and a current ratio of 1.97. Gilead Sciences, Inc. has a 52-week low of $104.46 and a 52-week high of $157.29. The stock has a 50-day moving average of $134.56 and a 200-day moving average of $134.34.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion during the quarter, compared to analyst estimates of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business’s revenue was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post -0.79 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, June 15th. This represents a $3.28 annualized dividend and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is presently 44.69%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.